What a New York study found about Lenire

A Lenire study from a New York hearing clinic offers a closer look at how the device performs for US patients outside a clinical trial. Among people with moderate or worse tinnitus who came back for their 12-week visit, 81.8% had a meaningful drop in how much tinnitus affected their life. The study has real limits, and they are worth understanding alongside the headline number.

What Lenire is

Lenire is a prescription device authorized by the FDA through the De Novo pathway in March 2023 for adults with at least moderate tinnitus. It pairs sound played through headphones with mild electrical pulses on the surface of the tongue, an approach called bimodal neuromodulation. Researchers have suggested that stimulating two nerve pathways at once changes how the brain responds to tinnitus more than sound alone does. The FDA authorization covers temporary relief of tinnitus symptoms.

The FDA decision rested on a controlled trial called TENT-A3, which followed 112 people in Europe. The New York study looks at something that trial could not, which is how the device does in everyday US practice.

How the New York study worked

Audiologists at New York Hearing Doctors fitted 140 patients with Lenire between May 2023 and January 2024. Each person first had a hearing test, a tinnitus assessment, and counseling about tinnitus and ways to cope with it. They then used the device at home for up to an hour a day, with check-ins recommended at about 6 and 12 weeks.

Progress was measured with the Tinnitus Handicap Inventory, a 25-question survey scored from 0 to 100. A drop of at least 7 points is commonly treated as a meaningful change.

Most patients (104 of 140) started with moderate or worse tinnitus, which matches the FDA authorization. The clinic treated 36 people with slight or mild scores who still felt very bothered, after explaining that the device might be less likely to help them. The researchers then looked back through patient records. This kind of study is called a chart review, and it has no comparison group.

What the researchers found

For people who started with moderate or worse tinnitus, the study authors reported these results.

• At about 6 weeks, 72.6% had a meaningful improvement in their score.
• At about 12 weeks, 81.8% had a meaningful improvement, and the average score fell by about 24 points.
• Using a stricter 11-point standard, 71.2% still counted as improved at 12 weeks.
• More than half moved down into the mild or slight category by 12 weeks.

People who started with slight or mild tinnitus showed almost no change on average. The authors conclude that Lenire is best suited to people whose tinnitus bothers them at least moderately, which is the group the FDA authorization covers.

The clinic reported no treatment-related serious side effects and no safety reports that needed to go to the FDA.

What the study leaves open

A few points help keep these results in proportion.

• No comparison group. With no group using a different treatment or a placebo, the study cannot show how much of the change came from the device itself. Everyone received counseling before starting, and the authors note that its effect cannot be fully separated out.
• Some patients did not return. 51 of the 140 patients did not have a 12-week score. The authors suggest some may have skipped the visit because they were doing well, which the records cannot confirm.
• Ties to the maker. One author provides Lenire at the clinic, and another is a consultant with financial interests in Neuromod Devices, the company that makes it. Neuromod staff helped with the study's ethics submission and data checks. A monitor from outside the clinic checked the data against patient records, and the paper went through peer review.
• One clinic, three months. The results come from a single New York practice over about 12 weeks. They may not reflect every clinic, and they do not show how long any benefit lasts.

Read alongside TENT-A3, the study gives US patients a useful picture of how Lenire treatment runs in a real clinic and which patients tended to respond.

Find a clinic that offers Lenire

Lenire reaches patients through trained tinnitus clinicians, so you cannot buy it directly. A first visit usually covers your hearing, how much tinnitus affects your days, and whether the daily home sessions fit your routine. Every clinic listed on Tinnitus Support treats tinnitus, and you can filter our clinic directory by treatment to find clinics near you that offer Lenire. When you book, ask what is included in the treatment plan and how follow-up visits work.